z-logo
open-access-imgOpen Access
Evaluation of a real-time nucleic acid sequencebased amplification (nasba) assay for diagnosis of urogenital chlamydial infection
Author(s) -
Elena Shipitsyna,
Alevtina Savicheva,
N. E. Vorobyova,
E Sokolovsky,
Alexander Guschin,
Р. G. Ryzhikh,
German A. Shipulin,
P. N. Krotin,
L. V. Merculova,
О. Y. Landina
Publication year - 2005
Publication title -
žurnalʺ akušerstva i ženskihʺ boleznej
Language(s) - English
Resource type - Journals
eISSN - 1684-0461
pISSN - 1683-9366
DOI - 10.17816/jowd83578
Subject(s) - nasba , chlamydia trachomatis , genitourinary system , medicine , real time polymerase chain reaction , polymerase chain reaction , predictive value , virology , positive predicative value , nucleic acid amplification tests , chlamydia , nucleic acid , biology , immunology , rna , gene , biochemistry
This study was aimed to evaluate a new realtime nucleic acid sequence-based amplification (NASBA-Real- Time) assay for diagnosis of urogenital Chlamydia trachomatis infection. A total of 193 patients aged 16 to 42 (mean age, 22,8 years) were examined, with most of them having symptoms of urogenital infection. Cervical and urethral swabs from women and men, respectively, were investigated with the use of cell culture method, polymerase chain reaction (PCR) and NASBA- Real-Time. C. trachomatis infection was diagnosed in 29 patients (15 %): in 21 patients - by all the three methods, whereas 8 samples were culture negative. Sensitivity of PCR and NASBA- Real-Time methods were 100 %, cell culture method - 78,4 %. Negative predictive value of PCR and NASBA-Real-Time was found to be 100 %, and that of cell culture - 95,3 %. Specificity as well as positive predictive values of all the three methods equaled 100%. Thus, the new real-time NASBA-Real-Time assay was shown to be a very sensitive and specific test, which can be recommended as a confirmatory method for diagnosis of urogenital chlamydial infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here